Overview

Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)

Status:
NOT_YET_RECRUITING

Trial end date:
2026-09-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-162 administered once daily for 2 weeks in subjects with cryopyrin-associated periodic syndrome (CAPS)

Phase:

PHASE1

Details

Lead Sponsor:

Akros Pharma Inc.

Collaborator:

PPD Development, LP